Published in Clinical Trials Week, September 25th, 2006
VivaGel is currently in development as a microbicide for the prevention of the sexually transmitted infections, genital herpes and HIV/AIDS. It has already been successfully tested in a phase 1 safety study in women. The trial announced is being conducted to provide safety data for VivaGel in men who may be exposed to product used by their female partners.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week